TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06303882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation treatment
Description: The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted Cognitive Function Training
Description: Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional cognitive training
Description: including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
Study: NCT06538129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypersensitivity prevention protocol with Er:YAG laser
Description: 1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using visual analogue scale (VAS); 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade,); 4.Placement of dental dam followed by photoactivation with Valo cordless curing light 5.Hypersensitivity prevention protocol with Er:YAG laser in cervical region (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital immediately after bleaching, 48 after bleaching and one week after bleaching.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypersensitivity prevention protocol with neutral sodium fluoride gel
Description: 1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using the VAS; 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade); 4.Placement of dental dam followed by photoactivation with Valo cordless; 5.Hypersensitivity prevention protocol with neutral sodium fluoride gel for 4 minutes (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital spectrophotometer immediately after bleaching, 48 after bleaching and one week after bleaching.
Study: NCT05440864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Pre-operatively Tremelimumab will be administered first for 1 hour; the Durvalumab infusion (1hr) will start approximately 1 hour (maximum 2 hours) after the end of the Tremelimumab infusion. Post-operatively patients will receive Durvalumab Q4W to complete up to 12 months of treatment or a maximum of 11 cycles of adjuvant Durvalumab
Study: NCT06669065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extraoral versus intraoral scanning techniques
Description: different data acquisition techniques for full-arch dental implants
Study: NCT06669130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xiangtong TM full degradation sinus drug stent system
Description: use Xiangtong TM full degradation sinus drug stent system to deliver drugs into sinus

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nasopore
Description: use nasopore to protect the post-operative sinus
Study: NCT06669637

Intervention type: DEVICE
Intervention: Ablation
Description: Ablation procedure for Atrial Fibrillation
Study: NCT05045664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Rituximab with 12 x 2 Gy involved site radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Obinutuzumab with 2 x2 Gy involved site radiotherapy
Study: NCT06470347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
Description: During treatment, subjects were given 400 mg pyrrotinib once daily, within 30 minutes after breakfast.
Study: NCT05646602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum
Description: Intralesional injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: Intralesional injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duolith SD1 T-TOP
Description: Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duolith SD1 T-TOP
Description: Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duolith SD1 T-TOP
Description: Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
Study: NCT05190900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neural mobilization
Description: neural mobilisation of the posterior tibial, deep peroneal and lateral, intermediate and medial dorsocutaneous nerves.
Study: NCT06008639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treatment group-Device: NirsCure - Active NirsCure - Active settings
Description: Treatment was performed once a day,5-6 times a week for 16 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo group-Device: NirsCure - Sham NirsCure - Sham settings
Description: Treatment was performed once a day,5-6 times a week for 16 weeks.
Study: NCT05250947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel® Concentrated Platelet Rich Plasma System
Description: Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint
Study: NCT06588491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: Standard lymphodepletion regimen
Study: NCT05492019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 50 mg capsule twice daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo identical to Doxycycline
Study: NCT05052515

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts
Description: Patients with NAFLD will be randomly allocated to receive Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with NAFLD will be randomly allocated to receive placebo
Study: NCT06669000

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard X-Rays
Description: - Standard X-Rays: feet (Month 0)

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: - Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.

Intervention type: DIAGNOSTIC_TEST
Intervention: DECT of feet
Description: DECT of feet: in tophaceous patients only (Month 0, Month 24)
Study: NCT05430568

Intervention type: PROCEDURE
Intervention: robot-assisted surgery
Description: 1. traditional sternotomy for coronary bypass graft or valvular replacement~2. robot-assisted surgery for coronary bypass graft or valvular replacement

Intervention type: PROCEDURE
Intervention: robot-assisted surgery
Description: 1. traditional sternotomy for coronary bypass graft or valvular replacement~2. robot-assisted surgery for coronary bypass graft or valvular replacement
Study: NCT06428526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous stimulation strategy
Description: Participants will be administered stimulation with a constant frequency stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous stimulation strategy
Description: Participants will be administered stimulation with a constant frequency stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation strategy
Description: Participants will be administered with an activity-dependent stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation strategy
Description: Participants will be administered with an activity-dependent stimulation.
Study: NCT05504616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health technology-based intervention strategy
Description: Patient-centered, technology-based intervention strategy aimed at increasing physical activity in patients with axSpA
Study: NCT06045975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
Description: * Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by IRE procedure at Day 30+/-7 days~* 11 monthly Durvalumab 1500 mg infusions.
Study: NCT06456398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Through a randomized controlled trial, educational training will be designed, and pre- and post-tests will be conducted to compare the effectiveness of learning advanced anatomy using the Metaverse Virtual 3D Printing System in virtual reality, versus the traditional method of using flat diagrams to correlate with computed tomography scans.
Study: NCT06181682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intranasal midazolam
Study: NCT06669000

Intervention type: BIOLOGICAL
Intervention: DNA sample
Description: DNA will be collected at Month 0

Intervention type: BIOLOGICAL
Intervention: Serum collection
Description: - Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.
Study: NCT06670911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Pembrolizumab Plus Chemotherapy (Paclitaxel plus Carboplatin or Cisplatin)
Description: Patients will receive pembrolizumab 100mg IV every 3 weeks plus chemotherapy (paclitaxel 175 mg/m² + carboplatin AUC 5 or paclitaxel 175 mg/m² + cisplatin 50 mg/m² for cisplatin-naïve patients).
Study: NCT05261100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises
Description: Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises..

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform.
Study: NCT06626191

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Interscalene brachial plexus block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus posterior superior intercostal plane block
Description: Patients will undergo serratus posterior superior intercostal plane block using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study: NCT04728737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: swallowing therapy
Description: oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: swallowing therapy
Description: oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
Study: NCT04745455

Intervention type: OTHER
Group type: OTHER
Intervention: Infant formula containing prebiotics, probiotics and postbiotics
Description: Infant formula containing prebiotics, probiotics and postbiotics
Study: NCT06006754

Intervention type: OTHER
Intervention: Observational study
Description: No intervention: observational study
Study: NCT05472194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InSchool Training Program
Description: The goal of the intervention is to promote and boost the development of executive functions in preschool and elementary school-aged children by means of engagement in meaningful and challenging activities. The method to achieve this consists on weekly intervention sessions run by teachers with a set of games specially developed to train executive functions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular school activities
Description: Children in the control group will be playing with the regular school activities.
Study: NCT04728737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IOPI therapy
Description: tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular electrical stimulation (NMES) therapy
Description: The neuromuscular electrical stimulation (NMES) therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the clinical swallowing disorders with for oropharyngeal muscles~(1 hour/session for 10 sessions)
Study: NCT06626191

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group without peripheral nerve block
Description: In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study: NCT05527028

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Occupational Therapy Services
Description: Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
Study: NCT04627870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug (paclitaxel) coated balloon
Description: use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA balloon
Description: use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis
Study: NCT05527028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Services
Description: Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
Study: NCT05798871

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival erythritol air polishing
Description: The intervention will start with supragingival debridement followed by subgingival erythritol air polishing by perioflow.~subgingival debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional root planing
Description: The intervention will start with supragingival debridement followed by root planing by curette.
Study: NCT05422118

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ascitic fluid calprotectin
Description: ascitic fluid calprotectin

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ascitic fluid calprotectin
Description: ascitic fluid calprotectin
Study: NCT06237140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF+ biofeedback exercise group
Description: Neurorehabilitation will be applied to this group, 5 sessions a week for 4 weeks, to increase balance and walking skills and reduce the risk of falling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF+ biofeedback exercise group
Description: Neurorehabilitation will be applied to this group, 5 sessions a week for 4 weeks, to increase balance and walking skills and reduce the risk of falling.
Study: NCT04927819

Intervention type: DEVICE
Intervention: BTI Implant
Description: BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).

Intervention type: DEVICE
Intervention: BTI Implant
Description: BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).
Study: NCT06460987

Intervention type: DRUG
Intervention: Finerenone
Description: Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels

Intervention type: DRUG
Intervention: Finerenone
Description: Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels

Intervention type: DRUG
Intervention: RAS inhibitor
Description: Receive RAS inhibitor treatment as specified in the KDIGO guidelines

Intervention type: DRUG
Intervention: RAS inhibitor
Description: Receive RAS inhibitor treatment as specified in the KDIGO guidelines

Intervention type: DRUG
Intervention: RAS inhibitor
Description: Receive RAS inhibitor treatment as specified in the KDIGO guidelines

Intervention type: DRUG
Intervention: RAS inhibitor
Description: Receive RAS inhibitor treatment as specified in the KDIGO guidelines

Intervention type: DRUG
Intervention: Immune Suppressant
Description: Receive immune suppressant treatment as specified in the KDIGO guidelines

Intervention type: DRUG
Intervention: Immune Suppressant
Description: Receive immune suppressant treatment as specified in the KDIGO guidelines
Study: NCT05023447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIDGE Intervention
Description: Intensive clinical assessment; \>16 sessions of Cognitive Analytic Therapy (CAT); Development of a shared formulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Service as Usual
Description: Likely to range from social services, mental-health services, forensic services to no intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Service as Usual
Description: Likely to range from social services, mental-health services, forensic services to no intervention
Study: NCT05627908

Intervention type: OTHER
Intervention: Contrast-enhanced ultrasound
Description: Patients data monitoring with medium- and high-grade trauma to the liver, spleen, and kidney
Study: NCT04906200

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to YES portal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete survey